Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 10.00
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.50 (5.00%)
Open: 10.25
High: 10.25
Low: 10.25
Prev. Close: 10.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DNA ImmunoBody Patent Granted in Europe

26 Jun 2017 07:00

RNS Number : 0805J
Scancell Holdings Plc
26 June 2017
 

26 June 2017

 

Scancell Holdings Plc

("Scancell" or the "Company")

 

DNA ImmunoBody® Patent Granted in Europe

 

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has now been granted in Europe.

 

The European patent, number 2134357, granted by the European Patent Office, covers Scancell's DNA ImmunoBody® platform technology and is key to the protection of the Company's pipeline of ImmunoBody® vaccines, including lead candidates, SCIB1 and SCIB2.

 

On issuance, this patent will extend coverage of Scancell's intellectual property into another important market for Scancell. Counterparts to this patent have already been granted in the United States, Australia and Japan.

 

The European patent covers the following countries: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey.

 

Dr. Richard Goodfellow, Chief Executive Officer of Scancell, commented:

 

"The addition of this key European patent for DNA ImmunoBody® significantly bolsters our global intellectual property portfolio as we position the company for future growth."

 

 

For Further Information:

 

Dr John Chiplin, Executive Chairman

Dr Richard Goodfellow, CEO

Scancell Holdings Plc

 

+1 858 900 2646

+44 (0) 20 3727 1000

Freddy Crossley (Corporate Finance)

Tom Salvesen (Corporate Broking)

Panmure Gordon & Co

+44 (0) 20 7886 2500

+44 (0) 20 7886 2500

Mo Noonan/Simon Conway

FTI Consulting

+44 (0) 20 3727 1000

 

About Scancell

 

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

 

Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

 

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

 

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. Experimental data suggests that the high avidity T cells induced by ImmunoBody® vaccines increase expression of PDL-1 on the tumour cell surface, thereby making the tumours more sensitive to checkpoint inhibitor drugs. Re-challenging animals with tumour cells after SCIB1 treatment resulted in 100% survival suggesting that ImmunoBody® induces a powerful memory response. Such an effect has not been observed with checkpoint inhibitors.

 

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKPDKCBKDKAB
Date   Source Headline
28th Mar 20241:21 pmRNSScancell Appoints WG as Joint Broker
26th Mar 202412:22 pmRNSFirst iSCIB1+ patient dosed
14th Mar 202411:17 amRNSAppointment of Sath Nirmalananthan to the Board
12th Mar 20247:00 amRNSScancell Attendance at Upcoming Conferences
4th Mar 20247:00 amRNSPresenting at Next-Gen Immuno-Oncology Conference
20th Feb 20247:00 amRNSChange of Auditor
5th Feb 20247:00 amRNSDirectorate Change
30th Jan 20247:00 amRNSInterim Results
26th Jan 20247:00 amRNSNotice of Interim Results and Presentation
17th Jan 20241:46 pmRNSUpdate on SCOPE trial
28th Dec 20235:36 pmRNSHolding(s) in Company
27th Dec 202311:38 amRNSHolding(s) in Company
19th Dec 20237:00 amRNSResult of the Open Offer
6th Dec 202312:41 pmRNSPDMR Notification
1st Dec 20237:00 amRNSResults of Placing
30th Nov 20235:03 pmRNSProposed Capital Raise to raise approximately £6m
29th Nov 20232:35 pmRNSResult of AGM
28th Nov 20237:00 amRNSUpdate on SCOPE trial
10th Nov 20238:32 amRNSScancell to present at 20th SMR Congress
1st Nov 20237:00 amRNSScancell to present at 38th Annual SITC meeting
31st Oct 202312:00 pmRNSNotice of AGM
31st Oct 20237:00 amRNSResults for the Year Ended 30 April 2023
20th Oct 20237:00 amRNSUpdate on Final Results
18th Oct 20237:00 amRNSScancell to speak at World Vaccine Congress Europe
17th Oct 20237:00 amRNSBlock Listing Six Monthly Return
11th Oct 20237:00 amRNSChange of Date for Final Results
3rd Oct 20237:00 amRNSNotice of Final Results and Investor Presentation
19th Sep 20237:00 amRNSPositive data from Phase 2 SCOPE trial with SCIB1
14th Sep 20237:00 amRNSScancell to present three posters at ICI
7th Sep 20237:00 amRNSScancell Appoints Head of Business Development
29th Aug 20237:00 amRNSScancell Appoints Sath Nirmalananthan as CFO
31st Jul 20237:00 amRNSModi-1 trial open for expansion in CPI combination
13th Jul 20239:14 amRNSExtension of exercise period for CEO share options
10th Jul 20237:00 amRNSPipeline strategy and business update
2nd Jun 20237:00 amRNSScancell to Present Modi-1 Data at ASCO
21st Apr 20237:00 amRNSIssue of share options to Non-Executive Directors
18th Apr 20237:00 amRNSModiFY Phase 1/2 poster presentation at AACR 2023
17th Apr 20237:00 amRNSBlock Listing Application to AIM
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank (SVB)
21st Feb 20239:05 amRNSSecond Price Monitoring Extn
21st Feb 20239:00 amRNSPrice Monitoring Extension
21st Feb 20237:00 amRNSEncouraging early efficacy data from ModiFY trial
13th Feb 20237:00 amRNSPositive response in COVIDITY trial
8th Feb 20237:00 amRNSIssue of Equity
1st Feb 20237:00 amRNSDr Jean-Michel Cosséry appointed as Chairman
25th Jan 20237:00 amRNSInterim Results
18th Jan 20237:00 amRNSNotice of Interim Results
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20223:18 pmRNSResult of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.